Open Trial of Bupropion SR in Adolescent Major Depression

Glod, Carol A.; Lynch, Arlene; Flynn, Elizabeth R.; Berkowitz, Cynthia; Baldessarini, Ross J.

doi:10.1111/j.1744-6171.2003.00123.x

Cited by 34 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…223 No pediatric RCTs of bupropion examining its effects on body weight have been published, although some short-term open-label studies suggest its use may be associated with small amounts of weight loss in adolescents. 224,225 …”

Section: Pharmacological Approaches To Treat Pediatric Obesitymentioning

confidence: 99%

An evolving scientific basis for the prevention and treatment of pediatric obesity

et al. 2014

View full text Add to dashboard Cite

The 2013 Pennington Biomedical Research Center’s Scientific Symposium focused on the treatment and management of pediatric obesity and was designed to (i) review recent scientific advances in the prevention, clinical treatment and management of pediatric obesity, (ii) integrate the latest published and unpublished findings and (iii) explore how these advances can be integrated into clinical and public health approaches. The symposium provided an overview of important new advances in the field, which led to several recommendations for incorporating the scientific evidence into practice. The science presented covered a range of topics related to pediatric obesity, including the role of genetic differences, epigenetic events influenced by in utero development, pre-pregnancy maternal obesity status, maternal nutrition and maternal weight gain on developmental programming of adiposity in offspring. Finally, the relative merits of a range of various behavioral approaches targeted at pediatric obesity were covered, together with the specific roles of pharmacotherapy and bariatric surgery in pediatric populations. In summary, pediatric obesity is a very challenging problem that is unprecedented in evolutionary terms; one which has the capacity to negate many of the health benefits that have contributed to the increased longevity observed in the developed world.

show abstract

Section: Pharmacological Approaches To Treat Pediatric Obesitymentioning

confidence: 99%

An evolving scientific basis for the prevention and treatment of pediatric obesity

et al. 2014

View full text Add to dashboard Cite

show abstract

“…(66) In adults with CD, bupropion, a dopaminergic/noradrenergic reuptake blocker and TNF-alpha inhibitor, has shown to improve depression and inflammation (67, 68) and has also been effective in patients with severe fatigue in other inflammatory diseases (39–42). Both SSRIs and bupropion are relatively well-tolerated in other pediatric cohorts with depression and medically ill adults (69–72) but placebo response can also be present. Many antidepressants have been linked to gastrointestinal side effects (e.g., nausea, pain, diarrhea, and risk of gastrointestinal bleeding) that need to be particularly monitored.…”

Section: Treatment Considerationsmentioning

confidence: 99%

Pediatric inflammatory bowel disease and depression

Keethy

Mrakotsky

Szigethy

2014

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of review Depression in pediatric inflammatory bowel disease (IBD) is increasingly recognized to be a heterogeneous condition with diverse underlying predisposing and precipitating factors. Although there is a growing awareness regarding the benefits of integrating behavioral health into medical care, the way psychiatric treatments can best target different aspects of depression and related dysfunction has not been systematically explored. Recent findings This review discusses neurobiological risk factors for depression in IBD including inflammation, associated anti-inflammatory treatment with corticosteroids, pain, and sleep disturbance, as well as psychosocial factors including reactions to illness, illness perception, and disease and environmental stressors with emphasis of how these factors can influence treatment decisions. Empirically-supported psychosocial and psychopharmacological interventions are discussed within this context. Summary Understanding the diverse pathways that can lead to depression in youth with IBD can lead to the development of more targeted interventions and better integration of psychosocial care into the medical treatment of IBD.

show abstract

“…Recent clinical studies suggest that it is also used in the treatment of NIC dependence in adolescents [Niederhofer and Huber, 2004;Upadhyaya et al, 2004], although its effectiveness in young smokers is not clearly demonstrated. BUP is also one of the most prescribed antidepressants in adolescents with major depression [Glod et al, 2003;Williams et al, 2004], although there are no double-blind placebocontrolled studies about the efficacy and safety of this drug in the treatment of children and adolescents suffering mood disorders [Wagner, 2005].…”

Section: Introductionmentioning

confidence: 99%

Differential sensitivity to the effects of nicotine and bupropion in adolescent and adult male OF1 mice during social interaction tests

Gómez

Carrasco

Redolat

2008

Aggressive Behavior

View full text Add to dashboard Cite

Few studies have compared the action of both nicotine (NIC) and bupropion (BUP), an antidepressant used to treat NIC dependence, on social and aggressive behavior at different ages. This study aims to determine whether these drugs produce differential effects in adolescent (postnatal day: 36-37) and adult (postnatal day: 65-66) mice that have been housed individually for 2 weeks in order to induce aggressive behavior. Mice received BUP (40, 20, or 10 mg/kg), NIC (1, 0.5, and 0.25 mg/kg as base), or vehicle earlier to a social interaction test. BUP (40 mg/kg) decreased social investigation and increased nonsocial exploration in both adolescent and adult mice. The same effects were also observed in adult mice administered with a lower dose of the same drug (20 mg/kg). In adolescents, NIC (1 mg/kg) decreased social investigation, but this effect did not reach statistical significance in adults. In conclusion, a differential sensitivity to the effects of NIC or BUP emerged in some of the behavioral categories when the two age groups were compared.

show abstract

Open Trial of Bupropion SR in Adolescent Major Depression

Abstract: In this preliminary, small open study, depressed adolescents showed a marked response to bupropion SR.

Cited by 34 publications

References 20 publications

An evolving scientific basis for the prevention and treatment of pediatric obesity

An evolving scientific basis for the prevention and treatment of pediatric obesity

Pediatric inflammatory bowel disease and depression

Differential sensitivity to the effects of nicotine and bupropion in adolescent and adult male OF1 mice during social interaction tests

Contact Info

Product

Resources

About